Hidradenitis suppurativa

Research projects

  • Hidradenitis suppurativa prospective patient registry and multidisciplinary team meeting outcomes
  • Characterising the microbiology of deroofed lesions of hidradenitis suppurativa
  • Hidradenitis suppurativa digital algorithm project (HSDAP)
  • Cross-sectional survey-based study reveals impact of hidradenitis suppurativa on quality of life is worse than myocardial infarction 
  • What are the barriers to lifestyle modifications in patients with HS? How can healthcare workers help?
  • Cross-sectional survey-based study reveals self-diagnosis of Hidradenitis Suppurativa via internet search in over 10% of patients
  • Hidradenitis suppurativa wound care management, its challenges and patient led dressing design
  • The profound negative impact of hidradenitis suppurativa on sexual health: a qualitative analysis

Clinical trials

  • Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa (STOP-HS2) - INCB 54707-302

If you have any questions regarding clinical trials or are interested in participating, please reach us at HS-Derm@health.qld.gov.au.

Patient resources


Email: HS-Derm@health.qld.gov.au


Liu TJ, McMeniman EK. Pityriasiform drug eruption associated with venetoclax for acute myeloid leukaemia. Anti-Cancer Drugs. 2024 Mar 22:10-97.

Merchant MA, Liu T, McMeniman E, Lambie D. Granuloma formation is insufficient for differentiating hidradenitis suppurativa and cutaneous Crohn’s disease. Pathology. 2024 Feb 1.

Kozera EK, Porter M, Paek SY, Mintoff D, McMeniman E, Oon HH, Chandran NS, Glasenhardt K, Ring HC, Frew JW. Infectious Disease Screening Prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation. Dermatology (Basel, Switzerland). 2023 Nov 14.

Liu T, McMeniman E. An overview of hidradenitis suppurativa. Dermatology Republic. 2023.

Long V, Choi EC, Chen Z, Kamil MA, Rajagopalan M, McMeniman E, Chandran NS. Dermatologists’ perceptions of the use of teledermatology in managing hidradenitis suppurativa: survey study. JMIR dermatology. 2023 Jan 31;6:e43910.

Liu TJ, Lin LL, McMeniman E, Wu J, Kao YC, Kumari S, Boyle GM, Wells JW, Soyer HP, Gonzalez-Cruz JL. Cytokine/chemokine assessment as a complementary diagnostic tool for inflammatory skin diseases. Frontiers in Immunology. 2022 Nov 16;13:1028435.

Mortimore AM, Bullen A, McMeniman EK. The impact of hidradenitis suppurativa on quality of life is worse than inflammatory bowel disease and myocardial infarction. Australasian Journal of Dermatology. 2022 Nov;63(4):505-8.

Mortimore AM, Bullen A, McMeniman EK. Cross-sectional survey based study reveals self diagnosis of hidradenitis suppurativa via Internet search in over 10% of patients. Australasian Journal of Dermatology. 2022 Aug;63(3):385-7.

Mortimore A, Bullen A, McMeniman E. Is Doctor Google helpful for diagnosing Hidradenitis Suppurativa?. In Australasian Journal of Dermatology 2022 May 1 (Vol. 63, pp. 73-74). 111 River St, Hoboken 07030-5774, NJ USA: Wiley.

Vitali J, Morgan E, Wagels M, McMeniman E, Law B, Lloyd T, Wiper J. Squamous cell carcinoma in hidradenitis suppurativa: Case report of a novel surgical treatment for an aggressive tumour. Australasian Journal of Dermatology. 2022 Feb;63(1):e90-1.